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Purpose or Objective: The majority of patients with 
follicular lymphoma (FL) present with advanced disease and 
are considered incurable. For patients with localised stage I 
or contiguous stage II, radiotherapy (RT) may be curative, but 
a significant proportion will relapse, usually at distant sites. 
Historical series report progression free survival (PFS) rates 
at 5 & 10 years post RT of 50-60% and 40-50% respectively.  
PET-CT using Fluorodeoxyglucose (FDG) is superior to CT for 
staging of FL, with upstaging reported in 10-60% of patients. 
PET-CT has recently been recommended as the standard 
imaging modality for staging of FL.  
By measuring outcomes in patients who underwent radical RT 
for stage I/II FL staged by PET-CT, this study aims to test the 
hypothesis that more accurate staging improves selection for 
localised RT and consequent patient outcome.  
 
Material and Methods: A retrospective review was 
undertaken of all patients who underwent radical RT for 
stage I and II FL (grade 1, 2, 3a) at our institution from 2006-
2014 staged by PET-CT. Patients were newly diagnosed and 
had not received any prior systemic or radiation therapy. 
Sex, age, PET-CT stage, LDH level, FLIPI score were recorded 
and whether a bone marrow trephine (BMT) was performed. 
RT site and dose were documented. Outcomes included 
relapse within the radiation field, distant relapse and PFS.  
 
Results: Between July 2006 and November 2014, twenty-
seven patients received radical involved field RT for stage I 
or contiguous stage II FL. 11 were male and 16 female. 
Median age (range) at RT was 59 years (32-84). 11 patients 
had grade 1 FL, 5 grade 1-2, 7 grade 2 and 5 grade 3a. 23 of 
27 (85.2%) had Ann Arbor stage I disease by PET-CT. 23/27 
(85.2%) had a BMT prior to treatment. In 3 cases BMT was not 
performed and in 1 the sample was inadequate. FLIPI score 
was 0-1 in all cases. The radiation dose was 24Gy/12# or 
30.6Gy/17#, with the majority receiving 30.6Gy (23/27, 
85.2%).  
With a median follow up of 59.6 months (10.6-104), 23/27 
(85.2 %) remain free of relapse either within or outside the 
radiation field. There have been no in-field recurrences. 4 
patients (14.8%) have relapsed at distant nodal sites. The 4 
relapses occurred at 3, 3, 9 and 25 months post treatment. 5 
year PFS estimate was 84.75% (95% CI 71.01- 98.59) (see 
figure 1). For patients with stage 1 by PET-CT, 5 year PFS 
estimate was 90.87% (95% CI 68.2-97.9) and for those with 
stage 2, 50% (95% CI 6.6-.84.2). All patients were alive at 
completion of the study.  
 
Conclusion: PFS after local RT for stage I/II FL staged by 
PET-CT appears to be better than for those historically 
staged by CT. Longer follow up and more patients are needed 
to confirm our findings, but this study suggests that earlier 
series from the pre-PET-CT era may have underestimated the 
efficacy of RT as a curative treatment for truly localised FL. 
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Purpose or Objective: In 2015 the International Lymphoma 
Radiation Oncology Group (ILROG) has published guidelines 
on field and dose for modern radiotherapy in extranodal 
lymphomas. Involved site radiation therapy (ISRT) is 
recommended, and for most cases, ISRT results in smaller 
radiation fields than the involved-field radiation (IFRT) used 
previously. We analyzed our treatment plans to determine 
the compliance to ILROG guidelines in extranodal lymphomas. 
 
Material and Methods: This retrospective study is based on 
the medical records of 62 patients with extranodal 
lymphoma, who were treated with definitive radiotherapy at 
our institute between 2011 and 2014. The patients 
characteristics are shown in Table 1. After evaluating the 
compliance to ILROG guidelines for each RT plan, Fisher’s 
exact test was performed to determine factors associated 
with non-standard treatment including tumor site, histology, 
and radiation technique (IMRT vs. conventional technique). 
We calculated the progression free survival (PFS) by site and 
histology, and compared our findings to reference data 
retrieved from the IELSG trials. 
 
 
 
Results: Forty-four (71%) patients were treated according to 
ILROG guidelines, and eighteen did not receive a standard 
teratment, either due to non standard treatment volume 
(n=13) or due to radiation dose (n=5).The major deviations 
from ILROG guidelines were observed in patients affected by 
pharynx lymphoma and orbital lymphoma. All patients with 
pharynx lymphoma underwent whole-Waldeyer ring RT 
instead of ISRT, while all patients with orbital lymphoma 
underwent partial-orbital RT instead of recommended whole-
orbital RT. The majority (61%) of patients managed with 
nonstandard treatment were treated with IMRT technique. 
PFS by site and histology were similar to those reported in 
the IELSG trials. 
 
Conclusion: This plans review process resulted in a high 
compliance to ILROG guidelines (71%). We identified a subset 
of patients which did not receive a standard treatment, 
therefore we are revising our treatment policy for pharynx 
lymphoma and orbital lymphoma. 
 
 
 
 
